TEE
OPRX icon

Tibra Equities Europe’s OptimizeRx OPRX Stock Holding History

Tibra Equities Europe’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,602
Closed -$338K – 386
2019
Q1 		$338K Buy
+26,602
New +$346K 0.03% 317

Other funds holding OPRX

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

Tibra Equities Europe's OPRX Position: Q2 2019 in Review

Tibra Equities Europe sold out of OptimizeRx (OPRX) in Q2 2019, closing a stake of 26,602 shares — an estimated $338K sold.

Tibra Equities Europe first reported a position in OPRX in Q1 2019 and held it in 1 quarter. The position peaked at $338K in Q1 2019. 56 funds tracked by Wall St. Rank hold OPRX as of Q2 2019.

  • Tibra Equities Europe reported no remaining OptimizeRx position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 26,602 OptimizeRx shares in Q2 2019, an estimated $338K.
  • Tibra Equities Europe first reported a position in OptimizeRx in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's OptimizeRx position peaked at $338K in Q1 2019.
  • 56 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.